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Abstract: INTRODUCTION This is the first German evidence- and consensus-based clinical guideline
on diagnosis, treatment, and follow-up on germ cell tumours (GCTs) of the testis in adult patients.
We present the guideline content in two publications. Part I covers the topic’s background, methods,
epidemiology, classification systems, diagnostics, prognosis, and treatment recommendations for the lo-
calized stages. METHODS An interdisciplinary panel of 42 experts including 1 patient representative
developed the guideline content. Clinical recommendations and statements were based on scientific evi-
dence and expert consensus. For this purpose, evidence tables for several review questions, which were
based on systematic literature searches (last search was in March 2018) were provided. Thirty-one ex-
perts entitled to vote, rated the final clinical recommendations and statements. RESULTS We provide
161 clinical recommendations and statements. We present information on the quality of cancer care and
epidemiology and give recommendations for staging and classification as well as for diagnostic proce-
dures. The diagnostic recommendations encompass measures for assessing the primary tumour as well
as procedures for the detection of metastases. One chapter addresses prognostic factors. In part I, we
separately present the treatment recommendations for germ cell neoplasia in situ, and the organ-confined
stages (clinical stage I) of both seminoma and nonseminoma. CONCLUSION Although GCT is a rare
tumour entity with excellent survival rates for the localized stages, its management requires an interdis-
ciplinary approach, including several clinical experts. Quality of care is highly related to institutional
expertise and can be reassured by established online-based second-opinion boards. There are very few
studies on diagnostics with good level of evidence. Treatment of metastatic GCTs must be tailored to
the risk according to the International Germ Cell Cancer Collaboration Group classification after careful
diagnostic evaluation. An interdisciplinary approach as well as the referral of selected patients to centres
with proven experience can help achieve favourable clinical outcomes.
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Abstract
Introduction: This is the first German evidence- and con-
sensus-based clinical guideline on diagnosis, treatment, 
and follow-up on germ cell tumours (GCTs) of the testis in 
adult patients. We present the guideline content in two 
publications. Part I covers the topic’s background, meth-
ods, epidemiology, classification systems, diagnostics, 
prognosis, and treatment recommendations for the local-
ized stages. Methods: An interdisciplinary panel of 42 ex-
perts including 1 patient representative developed the 
guideline content. Clinical recommendations and state-
ments were based on scientific evidence and expert con-
sensus. For this purpose, evidence tables for several review 
questions, which were based on systematic literature 
searches (last search was in March 2018) were provided. 
Thirty-one experts entitled to vote, rated the final clinical 
recommendations and statements. Results: We provide 
161 clinical recommendations and statements. We present 
information on the quality of cancer care and epidemiology 
and give recommendations for staging and classification as 
well as for diagnostic procedures. The diagnostic recom-
mendations encompass measures for assessing the prima-
ry tumour as well as procedures for the detection of metas-
tases. One chapter addresses prognostic factors. In part I, 
we separately present  the treatment recommendations for 
germ cell neoplasia in situ, and the organ-confined stages 
(clinical stage I) of both seminoma and nonseminoma. Con-
clusion: Although GCT is a rare tumour entity with excellent 
survival rates for the localized stages, its management re-
quires an interdisciplinary approach, including several clin-
ical experts. Quality of care is highly related to institutional 
expertise and can be reassured by established online-based 
second-opinion boards. There are very few studies on diag-
nostics with good level of evidence. Treatment of metastat-
ic GCTs must be tailored to the risk according to the Inter-
national Germ Cell Cancer Collaboration Group classifica-
tion after careful diagnostic evaluation. An interdisciplinary 
approach as well as the referral of selected patients to cen-
tres with proven experience can help achieve favourable 
clinical outcomes. © 2021 The Author(s)
Published by S. Karger AG, Basel
Background
The incidence of germ cell tumours (GCTs) of the tes-
tis is low with about 10 out of every 100,000 men in Ger-
many per year [1]. However, the importance arises from 
the fact that GCTs represent the most common type of 
cancer in men aged 20–40 years, with 25% of all malig-
nancies diagnosed in this age group [1]. Survival rates are 
excellent for the localized stages (95–100%) and are still 
good for the metastasized stages (70–90%) [2]. Clinically, 
GCTs are classified into seminomas (about 60%) and 
non-seminomatous GCTs [1, 3].
For all stages, the tumour-specific therapeutic success 
depends on the correct diagnosis and staging, which is es-
sential to avoid under- but also overtreatment. Interdis-
ciplinary cooperation between urologists, oncologists, 
radio-oncologists, radiologists, and pathologists is man-
datory, especially for multidisciplinary therapy control in 
the metastatic poor prognosis and relapsed patient 
groups. In addition, established online-based second-
opinion boards enable urologists and oncologists to reas-
sure especially first-line treatment decisions [4–6].
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So far, no official evidence-based German clinical 
practice guideline on this topic has been available. There 
are interdisciplinary consensus recommendations [7, 8], 
which were developed by the interdisciplinary German 
Testicular Cancer Study Group (GTCSG) of the German 
Cancer Society. However, they are mainly based on ex-
pert consensus and do not follow the transparent and 
high-quality methodology development criteria set up by 
the Association of Scientific Medical Societies in Germa-
ny (AWMF) [9].
Therefore, the German Society of Urology (DGU) to-
gether with the interdisciplinary GTCSG initiated the de-
velopment of an S3 German-language clinical practice 
guideline on this topic. The guideline category S3 refers 
to a German guideline classification system in which S3 
represents the highest methodological standard. It in-
volves both evidence- and consensus-based concepts to 
achieve highest quality guideline recommendations from 
an interdisciplinary panel group [10].
The German S3 guideline is freely available for down-
load in both short and long versions: https://www.awmf.
org/leitlinien/detail/ll/043-049OL.html. A separate method 
report on the guideline development process is addition-
ally available.
Physicians and other medical service providers who 
are involved in the diagnostics, treatment, and follow-up 
of GCTs (all stages, outpatient and inpatient care as well 
as rehabilitation) are the target audience of the present 
guideline. A patient guideline for patients and lay persons 
will be published soon. The guideline also comprises 
quality indicators for measuring the implementation of 
the guideline recommendations in routine clinical care; 
these data will be presented in a future publication.
We present the English translation of the main content 
of this guideline in two separate parts, which includes all 
clinical recommendations and statements of the original 
guideline. Part I relates to epidemiology, classification 
systems, diagnostics, prognosis, and treatment recom-
mendations for the localized stages. Part II covers the 
treatment recommendations for the metastatic stages as 
well as relapsed and refractory disease, follow-up sched-
ules, toxicity management, quality of life, and palliative 
and supportive care.
Objective
The overall aim of the present project is to improve the 
treatment of GCT and thus increase survival of the pa-
tients afflicted with the disease. Also, quality of life of sur-
viving patients is intended to be improved by efforts to 
minimize acute and late toxicity of treatment.
For these goals, we aimed at developing the first Ger-
man guideline for the management of GCTs in adult pa-
tients that is explicitly based on formal scientific evidence 
and if required on consensus in a working group of dedi-
cated experts.
Methods
In the guideline development process, we followed the AWMF 
methodology for S3 guidelines [10]. This process is illustrated in 
Figure 1. For details, see the German method report (available at: 
https://www.awmf.org/leitlinien/detail/ll/043-049OL.html).
Members and Funding
The interdisciplinary panel for this guideline consisted of 32 
experts (including a patient representative) entitled to vote, as well 
as several external experts and working group leaders (see Table 1). 
The project was funded by the German Cancer Aid. Methodolog-
ical supervision was provided by the German Guideline Program 
in Oncology [11]. Conflicts of interest were disclosed by all guide-
line panel members and are available in the guideline report 
(http://www.awmf.org/leitlinien/detail/ll/043-044.html).
Set-up of interdisciplinary guideline panel, invitation of
representatives, kick-off meeting to define work packages 
Systematic literature searches
Literature screening, creation of evidence tables and
study quality appraisal
Chapter development in working groups based on current
evidence and expert consensus, statements and
recommendation development
Guideline panel review of preliminary version of guideline
Discussion and voting in the guideline consensus conference
Public external guideline review
Guideline publication
Fig. 1. Steps of the guideline development process.
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Table 1. Coordinators, medical societies, and organizations involved
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Prof. Dr. Jonas Busch
PD Dr. Julia Heinzelbecker
Prof. Dr. David Pfister




PD Dr. Friedemann Zengerling
Medical society or organization Participants in guideline development
German Society of Urology (DGU) Prof. Dr. Susanne Krege (deputy: Prof. Dr. Sabine Kliesch)
German Society of Radiation Oncology (DEGRO) Prof. Dr. Johannes Claßen (deputy: Prof. Dr. Rainer Souchon)
German Society of Andrology (DGA) Prof. Dr. Hans Schmelz (deputy: PD Dr. Kathleen Herkommer)
German Society for General and Visceral Surgery (DGAV) Prof. Dr. Marko Kornmann
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German Society for Nuclear Medicine (DGN) Prof. Dr. Jörg Kotzerke
German Association for Palliative Medicine (DGP) Dr. Matthias Gockel
German Society of Pathology (DGP) Prof. Dr. Stefan Schweyer (deputy: Prof. Dr. Glen Kristiansen)
German Society of Nursing Science (DGP) Heinrich Recken, B.A. (deputy: Prof. Dr. Stefanie Seeling)
German Society for Thoracic Surgery (DGT) Prof. Dr. Clemens Aigner
German Society of Radiology (DRG) PD Dr. Dirk Beyersdorff (deputy: Prof. Dr. Sascha Kaufmann)
Association of German Urologists (BvDU) Dr. med. Bernt Göckel-Beining (deputy: Dipl. Med. Roger Zillmann)
Association of German Pathologists (BVP) Prof. Dr. Glen Kristiansen (deputy: Prof. Dr. Stefan Schweyer)
Austrian Society of Urology and Andrology (ÖGU) PD Dr. Walter Albrecht (deputy: Dr. Renate Pichler)
Swiss Society of Urology (SGU) PD Dr. Thomas Hermanns
Pain and Supportive Therapy, Quality of Life, and Palliative Care Working 
Group (Arbeitskreis Schmerztherapie, Supportivtherapie, Lebensqualität, und 
Palliativmedizin)
Dr. Matthias Beintker (deputy: Prof. Dr. Oliver Hakenberg)
Oncology Working Group (AKO) Prof. Dr. Oliver Hakenberg
Supportive Measures in Oncology, Rehabilitation, and Social Medicine 
Working Group (ASORS)
Prof. Dr. Oliver Rick (deputy: Prof. Dr. Maike de Wit)
Internal Oncology Working Group (AIO) Prof. Dr. Carsten Bokemeyer (deputy: Dr. Annette Dieng)
Andrology Working Group (AKA) PD Dr. Diemer (deputy: PD Dr. Kathleen Herkommer)
Urological and Nephrological Diseases Rehabilitation Working Group (AKR) Prof. Dr. Ullrich Otto (deputy: Prof. Dr. Dirk-Henrik Zermann)
Oncological Pathology Working Group (AOP) Prof. Dr. Christian Wittekind
Oncologic Thoracic Surgery Working Group (AOT) Prof. Dr. Joachim Schirren
Palliative Care Working Group (APM) Prof. Dr. Karin Oechsle
Radiooncology Working Group (ARO) Prof. Dr. Heinz Schmidberger (deputy: PD Dr. Arndt-Christian Müller)
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Evidence and Recommendation Development
In January 2017, the scope of work and the work packages were 
defined during the first consensus conference held in Berlin, Ger-
many. Seventy-two key questions were defined, and afterwards 
several systematic literature searches were conducted using the da-
tabases Medline (via Ovid) and the Cochrane Library. The search 
period was from January 2010 to May 2017. A search update was 
performed in March 2018. Cohort studies, clinical trials, system-
atic reviews, meta-analyses, and international clinical guidelines 
were considered. We only included publications in English and 
German. Case reports, case series, case-control studies, editorials, 
commentaries, conference abstracts, and studies available in other 
languages were excluded.
For all studies included, relevant information was extracted in 
evidence tables, and the risk of bias was assessed according to study 
design, using AGREE [12], AMSTAR [13], the Cochrane tool for 
RCTs [14], SIGN [15], Quadas [16], and Quips [17]. The Oxford 
criteria were used for the level of evidence ratings [18] (Table 2). 
For the therapeutic key questions, the quality of the evidence was 
rated according to the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) approach [19].
The final evidence- and consensus-based recommendations 
and statements were elaborated, and a formal consensus of the 
guideline panel was achieved applying the nominal group tech-
nique under the guidance of an external moderator. The second 
and concluding consensus conference was held in Berlin in May 
2018. E-references are listed in the online supplementary eRefer-
ences file (see www.karger.com/doi/10.1159/000510407 for all on-
line suppl. material).
The following wordings were used for characterizing the 
strength of the clinical recommendations (see also Table 2):
• A: strong recommendation: “we recommend” or “is recom-
mended/is not recommended”
• B: weak recommendation: “should/should not”
• 0: inconclusive recommendation: “can”
Results
Chapter 3: Quality of Care
See also Table 3.
1 We recommend that patients with a metastatic GCT be-
longing to the poor prognosis group according to the In-
ternational Germ Cell Cancer Collaboration Group 
(IGCCCG) are treated at centres with proven experience 
(GRADE of recommendation A, level of evidence 2b) [4, 6].
2 We recommend that GCT patients with post-chemo-
therapeutic residual tumours receive residual tumour 
resection only after multidisciplinary consultation at 
centres with proven experience, which fulfil the pre-
requisites for multidisciplinary surgical interventions 
(expert consensus).
Chapter 4: Epidemiology, Risk Factors, Screening, and 
Prevention
1 In men aged 20–44 years, GCT is the most common 
malignant disease, accounting for about 25% of all 
cancers (statement, 2b) [1].
2 Within the last decades, the incidence of GCT has in-
creased to currently 10 out of every 100,000 men per 
year in all industrialized countries including Germany 
(raw disease rate) (statement, 2b) [1].
3 GCTs are among the cancers with highest survival 
rates. The patient’s prognosis essentially depends on 
tumour histology, clinical stage, age, and quality of 
care (statement, 2b) [1, 6].
Urological Oncology Working Group (AUO) Prof. Dr. Mark Schrader (deputy: Prof. Dr. Axel Heidenreich)
GTCSG (Hodentumorgruppe der Deutschen Krebsgesellschaft) Prof. Dr. Klaus Peter Dieckmann (deputy: PD Dr. Christian Ruf)
PRiO (Arbeitsgemeinschaft Prävention und integrative Medizin in der 
Onkologie)
Dr. Ivonne Rudolph
German Foundation for Young Adults with Cancer (Deutsche Stiftung für 
junge Erwachsene mit Krebs)
Timur Ohloff, M.Phil.
External experts Prof. Axel Heyll (MDK Competence Center Oncology)
Dr. Klaus Kraywinkel (Robert Koch Institute)
Dr. Ekkehard Ost (MDK Competence Center Oncology)
DGU, Deutsche Gesellschaft für Urologie; DEGRO, Deutsche Gesellschaft für Radioonkologie; DGA, Deutsche Gesellschaft für Andrologie; DGAV, 
Deutsche Gesellschaft für Allgemein und Viszeralchirurgie; DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie; DGN, Deutsche Gesellschaft 
für Nuklearmedizin; DGP, Deutsche Gesellschaft für Palliativmedizin; DGP, Deutsche Gesellschaft für Pathologie; DGP, Deutsche Gesellschaft für 
Pflegewissenschaften; DGT, Deutsche Gesellschaft für Thoraxchirurgie; DRG, Deutsche Röntgengesellschaft; BvDU, Berufsverband der Deutschen Urologen; 
BVP, Berufsverband Deutscher Pathologen; ÖGU, Österreichische Gesellschaft für Urologie und Andrologie; SGU, Schweizerische Gesellschaft für Urologie; 
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ARO, Arbeitsgemeinschaft Radiologische Onkologie; ATO, Arbeitsgemeinschaft Tumorklassifikation in der Onkologie; AUO, Arbeitsgemeinschaft 
Urologische Onkologie; GTCSG, German Testicular Cancer Study Group; PRiO, Prevention and Integrative Medicine in Oncology Working Group.
Table 1 (continued)
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4 Accepted pathogenetic risk factors for the develop-
ment of GCTs are previous contralateral GCT, history 
of maldescensus testis, positive family history, and 
male infertility (statement, 2b) [e20–e25].
5 General screening for the presence of a GCT is not rec-
ommended (A, 5) [e26–e28].
6 Regular self-examination of the testicles should be rec-
ommended especially to young men, as it can lead to 
early diagnosis (expert consensus).
7 In the presence of risk factors, the possibility of a GCT 
should be investigated (expert consensus).
Chapter 5: Pathological Classification
1 We recommend the 2016 WHO classification for the 
histopathological evaluation of GCTs [e29] (expert 
consensus).
Chapter 6: Diagnostics, Stages, and Classification 
Systems
See also Tables 3 and 4.
Imaging procedures in the context of local diagnostics 
and/or staging diagnostics:
1 On clinical suspicion of a GCT, we recommend to per-
form a physical examination as well as a bilateral tes-
ticular ultrasonography conducted with a high-resolu-
tion transducer involving at least 7.5 MHz (expert con-
sensus).
2 We recommend that men with newly diagnosed GCT 
receive a contrast-enhanced computed tomography 
(CT) scan of the abdomen/pelvis and chest for staging 
(A, 5) [e30, e31].
3 In patients with newly diagnosed GCT and contrain-
dications to iodine-containing contrast media, such 
as allergy, impaired renal function, or thyroid dys-
function, MRI of the abdomen/pelvis is recommend-
ed to replace a CT (A, 5) [e30]. In case of the above-
mentioned contraindications, a non-contrast-en-
hanced CT scan of the chest should be performed 
additionally to investigate pulmonary involvement 
(B, 5).




Ia SR (with homogeneity*) of level 1 diagnostic studies; clinical decision 
rule with 1b studies from different clinical centres
SR (with homogeneity*) of RCTs
Ib Validating cohort study with good reference standards or clinical 
decision rule tested within 1 clinical centre
Individual RCT (with narrow confidence interval)
Ic Absolute SpPins and SnNouts All or none principle
IIa SR (with homogeneity*) of level >2 diagnostic studies SR (with homogeneity) of cohort studies
IIb Exploratory cohort study with good reference standards, clinical 
decision rule after derivation, or validated only on split-sample or 
databases
Individual cohort study (including low quality 
RCT)
IIc Outcomes research, ecological studies
IIIa SR (with homogeneity*) of 3b and better studies SR (with homogeneity) of case-control studies
IIIb Non-consecutive study, or without consistently applied reference 
standards
Individual case-control study
IV Case-control study, poor or non-independent reference standard Case series (and poor-quality cohort and case-
control studies)
V Expert opinion without explicit critical appraisal, or based on 
physiology, bench research or first principles
Expert opinion without explicit critical appraisal, 
or based on physiology, bench research or first 
principles
RCT, randomized control trial; SR, systematic review. * By homogeneity, we mean a systematic review that is free of worrisome 
variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically 
significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant.
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4 Patients of the IGCCCG poor prognosis group as well 
as patients with excessive beta human chorionic go-
nadotropin (β-hCG) values, multiple pulmonary me-
tastases, or neurological symptoms should receive an 
additional cranial MRI (B, 5) [e28].
5 An FDG-PET/CT is not recommended for routine use 
in primary staging diagnostics (A, 1a) [e32].
6 FDG-PET/CT can be considered in seminoma pa-
tients with residual tumours larger than 3 cm in diam-
eter and with normal or normalized serum tumour 
markers after therapy completion (0, 1a) [e32]. The 
CT as part of the FDG-PET/CT examination should 
preferably be performed as contrast-enhanced CT (ex-
pert consensus).
7 Timing of FDG-PET/CT for the assessment of serum 
tumour marker-negative residual tumours in patients 
with seminoma is at the earliest recommended at 6 
weeks after the end of the last cycle of chemotherapy 
(expert consensus).
8 FDG-PET/CT is not recommended in patients with a 
non-seminomatous GCT (expert consensus).
Serum tumour markers (primary diagnostics and staging 
diagnostics):
9 We recommend determination of the serum tumour 
markers α-fetoprotein (AFP), β-hCG, and lactate de-
Table 3. Prognostic classification of metastatic GCT [2]a
Good prognosis group
Non-seminomatous 
GCT (56% of cases)
All of the following:
Testis/retroperitoneal primary
No non-pulmonary visceral metastases
AFP <1,000 ng/mL




All of the following:
Any primary site






GCT (28% of cases)
Testis/retroperitoneal primary
No non-pulmonary visceral metastases
Any of the following:
AFP ≥1,000 and ≤10,000 ng/mL or
hCG ≥5,000 and ≤50,000 IU/L or
LDH ≥1.5 and ≤10× ULN
Seminoma 
(10% of cases)








GCT (16% of cases)
(At least) one of the following: 
Mediastinal primary
Non-pulmonary visceral metastases
AFP >10,000 ng/mL or
hCG >50,000 IU/L (10,000 ng/mL) or
LDH >10× ULN
Seminoma No patients classified as poor prognosis
IGCCCG, International Germ Cell Cancer Collaboration 
Group; GCT, germ cell tumour; AFP, α-fetoprotein; hCG, human 
chorionic gonadotropin; LDH, lactate dehydrogenase; ULN, 
upper limit of normal. a For the staging, the serum tumour markers 
determined immediately prior to the start of chemotherapy (same 
day) are relevant.
Table 4. Recommended examinations for primary staging
Test Patients
Physical examination All patients






Chest/abdominal/pelvic CT All patients
Cranial MRI Symptomatic patients and 
patients in the IGCCCG 
poor prognosis group, or 
patients with multiple 
pulmonary metastases and/








Patients with unfinished 
family planning, active or 
postponed desire for 
offspring as well as for 
ruling out/detecting 
hypogonadism
AFP, α-fetoprotein; hCG, human chorionic gonadotropin; 
LDH, lactate dehydrogenase; CT, computed tomography; 
IGCCCG, International Germ Cell Cancer Collaboration Group; 
LH, luteinizing hormone; FSH, follicle-stimulating hormone. We 
recommend advising all patients on the cryopreservation of sperm 
preferably before the primary surgical intervention and, if 
necessary, arrange consultation with an andrologist or a fertility 
centre.
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hydrogenase in patients with suspected GCT prior to 
orchiectomy (expert consensus).
10 In patients with preoperatively elevated serum tumour 
marker levels, we recommend to monitor AFP, β-hCG, 
and lactate dehydrogenase postoperatively every 5–7 
days until normal values or nadir is reached, or until 
serum tumour markers increase (expert consensus).
Surgically determined diagnosis/inguinal exploration of 
the testis (including organ preservation):
11 If a GCT is suspected, we recommend inguinal testicu-
lar exploration and, in case of evidence for a malig-
nancy, radical orchiectomy of the respective testis is 
recommended (A, 5) [e28, e33].
12 In the presence of a healthy contralateral testis, organ-
preserving excision is not recommended in case of a 
unilateral malignant GCT (with the exception of a ter-
atoma without accompanying germ cell neoplasia in 
situ [GCNIS]) (expert consensus).
13 Organ-preserving tumour excision is recommended 
in patients with a bilateral GCT, with monorchid tu-
mour, in case of stromal or other benign tumours (epi-
dermoid cyst and monodermal teratoma), respectively 
(expert consensus).
Organ-preserving tumour resection in GCT:
14 For eradication of GCNIS after organ-preserving sur-
gery in monorchid tumour patients, we recommend 
adjuvant radiation of the affected testis with 18–20 Gy. 
As the development of a solid GCT from GCNIS may 
take several years, we recommend the discussion of 
regular sonographic controls with patients who de-
clined radiotherapy for the purpose of paternity and to 
those who are under surveillance (expert consensus).
15 We recommend that patients with increased risk for con-
tralateral GCNIS undergo contralateral biopsy at the time 
of orchiectomy after appropriate counselling (A, 4) [e34].
Pathological examination of the testicular tissue (includ-
ing GCNIS):
16 For patients with ultrasonographic testicular microli-
thiasis and no other risk factors, testicular biopsy is not 
recommended (A, 2a). A testicular biopsy can be con-
sidered in patients with microlithiasis presenting one 
of the following additional parameters: infertility, pre-
vious tumour disease of the testicle, first-degree rela-
tive with GCT, history of maldescended testis, or tes-
ticular atrophy with a sonographic testis volume <12 
mL (0) [e35].
17 We recommend that the pathohistological report on 
the testicular specimen includes the following infor-
mation: labelling of side, testicular size, maximum tu-
mour size (in 3 dimensions), macroscopic features of 
the epididymis, spermatic cord and tunica vaginalis, 
tumour in the surgical margins (yes/no), histological 
subtype with specification of individual components 
and percentage according to WHO 2016, tumoral ve-
nous and/or lymphatic invasion (yes/no), invasion of 
the tunica albuginea (yes/no), rete testis (yes/no), soft 
tissue of the hilum (yes/no) and the epididymis or 
spermatic cord (yes/no), GCNIS in non-tumorous pa-
renchyma (yes/no), and pT category according to the 
2017 TNM classification (expert consensus).
Fertility and cryopreservation of spermatozoa:
18 GCT therapy impairs the patients’ fertility to a variable 
extent, depending on the treatment regimen applied 
and the initial situation (statement, expert consensus).
19 We recommend that if a GCT is suspected, cryopreser-
vation of spermatozoa is offered to the patient before 
treatment initiation (before orchiectomy, at the latest 
before chemotherapy or radiotherapy) (A, 5) [e28, 
e36].
20 We recommend that patients with azoospermia at the 
time of scheduled cryopreservation prior to therapy 
are offered bilateral testicular sperm extraction (if pos-
sible simultaneously with orchiectomy) (A, 5) [e36].
Staging diagnostics and classification:
21 To characterize the anatomical spread of the GCT, we 
recommend the use of the current TNM classification 
(expert consensus).
Chapter 7: Prognosis
1 The stage-independent 5-year survival rate in patients 
with GCT (in Germany) is 97.9% for seminoma and 
94.9% for non-seminomatous GCT (statement, 2b) 
[1].
2 For stage I GCT patients, the cancer-specific 10-year 
survival rate is 99.7% and the 10-year overall survival 
rate is 95–99% (statement, 2b) [e37].
3 The 5-year survival rates for metastatic GCT are 86–
95% for patients in the good prognosis group, 72–85% 
for the intermediate prognosis group, and 48–64% for 
the poor prognosis group (statement, 2b) [2, e38].
4 In non-seminomatous GCTs, lymphovascular inva-
sion represents the only prospective multivariate anal-
ysis-validated risk factor for recurrence in clinical 
stage I (cSI) disease (statement, 2b). In seminoma, tu-
mour size correlates positively with the occurrence of 
recurrences in patients with cSI disease. Data on the 
impact of stromal rete testis infiltration are inconsis-
tent. With a tumour size of less than 4 cm and a lack of 
stromal rete testis infiltration, the risk of recurrence is 
minimal (<5%) (statement, 1b) [e39–e46].
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5 We recommend the classification of metastatic GCT 
to be based on the prognostic criteria of the IGCCCG 
(expert consensus).
Chapter 8: Primary and First-Line Therapy
Here, in part I, we outline the primary surgical treat-
ment of the testis and the treatment of the localized stag-
es. Part II of the publication will summarize all advanced 
disease stages.
Inguinal Exposure
In case of a testicular suspicious mass, the surgical in-
guinal exposure of the testis constitutes both diagnostics 
and therapy. Depending on the initial findings, it is per-
formed with or without frozen section-based intraopera-
tive assessment of the dignity of the tumour for either an 
organ-preserving approach (enucleation) or complete re-
moval of the testis (orchiectomy), including the spermat-
ic cord. In life-threatening disease due to metastatic 
spread, orchiectomy can be postponed and performed 
later in the course of the disease.
Rare giant tumours with a diameter of more than 10 
cm are an exception. In these cases, an inguino-scrotal 
approach including resection of the respective scrotal 
skin area should be applied [e47].
There are no data available that would justify scrotal 
orchiectomy as an exclusion criterion for a subsequent 
surveillance strategy. Cryopreservation of sperm should 
be performed before taking the first therapeutic step, 
which usually is orchiectomy (see above).
The insertion of a silicone implant during orchiecto-
my procedure should be discussed with and offered to the 
patient. This is not associated with an increased risk of 
infection. The overall surgical complication rate is about 
7% [e48]. The satisfaction rates (assessed by structured 
patient interviews) exceed 80% among these patients 
[e49, e50].
Therapy of GCNIS
1 In monorchid GCNIS, local radiotherapy with 18–20 
Gy attains eradication of GCNIS cells in more than 
95% of cases (statement, 2b) [e53, e54].
2 In case of active surveillance of GCNIS, an invasive 
GCT develops within 5 years in 50% of cases (state-
ment, expert consensus).
3 In case of unilateral GCNIS in the presence of a healthy 
contralateral testis, either orchiectomy or sonographic 
follow-up (active surveillance) are recommended (ex-
pert consensus).
4 In case of bilateral GCNIS, both testes should be irra-
diated (expert consensus).
5 After adjuvant chemotherapy, more than 50% of 
GCNIS cases develop into a manifest tumour. Addi-
tional radiotherapy should be performed (B, 2b) [e54, 
e55].
6 Radiotherapy of GCNIS-affected testes causes sterility. 
Prior cryopreservation of sperm (from the ejaculate or 
in the presence of azoospermia by means of a testicular 
sperm extraction) is recommended to be discussed 
with the patient (expert consensus).
7 After local radiotherapy with 18–20 Gy, long-term hy-
pogonadism can arise in 30% of cases. Regular controls 
Table 5. Recurrence rates in studies with non-seminomatous GCT 
patients in cSI [26–31]




[26] 43 2× PEB 2.5 42
[27] 114 2× PEB 1.7 48
[28] 42 2× PEB 4.8 79
[29] 58 2× PEB 1.7 93
[30] 40 2× PEB – 113.2
[31] 142 2× PEB 0.7 79
GCT, germ cell tumour; cSI, clinical stage I.
Table 6. Recurrence rates of chemotherapy versus surveillance in 
studies with non-seminomatous GCT patients in cSI [22–24, 32, 
33]



































GCT, germ cell tumour; cSI, clinical stage I; hr, high risk; lr, low 
risk.
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of the serum testosterone level are recommended (A, 
2b) [e53, e54].
8 Three or more cycles of cisplatin-based chemotherapy 
lead to eradication of GCNIS in 60–70% of cases. A 
control biopsy should be performed before radiother-
apy or, if the subsequent procedure depends on the 
result, 2 years after chemotherapy at the earliest (B, 2b) 
[e54, e55].
Seminoma in non-metastatic cSI:
9 In seminoma, the tumour size correlates positively 
with the presence of occult metastases in cSI. Data on 
stromal rete testis infiltration are inconsistent. With a 
tumour size of <4 cm and absence of rete testis infiltra-
tion, the risk of occult metastases is minimal (<5%) 
(statement, 2a) [e46].
10 All treatment options (active surveillance, adjuvant 
chemotherapy with carboplatin, and adjuvant radio-
therapy) achieve the same survival rates with stage-
adapted treatment of the disease in case of recurrence 
(statement, GRADE: very low quality of evidence) [e56–
e63].
11 Age, comorbidities, patient preferences, and patient 
compliance are recommended to be considered for the 
choice of therapy (expert consensus).
12 Patients with seminoma and cSI are recommended to 
be followed up by active surveillance and in case of re-
currence, they are treated according to stage-specific 
guidelines (A, GRADE: very low quality of evidence) 
[e57, e59, e60, e64–e67].
13 In patients with a tumour diameter >4 cm, adjuvant 
therapy can be considered in individual cases, espe-
cially if compliance concerns or psychological distress 
of the patient are suspected. One to 2 cycles of carbo-
platin (dosed according to AUC 7) or, alternatively, 
radiotherapy of the para-aortic region with 20 Gy are 
options for adjuvant therapy. Both therapeutic modal-
ities offer specific advantages and disadvantages, 
which are recommended to be discussed in detail with 
the patient (0, 2b) [e63, e68].
Non-seminomatous GCT in non-metastatic cSI:
14 The lymphovascular invasion of tumour cells in the 
primary tumour is the most important risk factor for 
occult retroperitoneal metastases. In the low-risk situ-
ation (without lymphovascular invasion), the risk of 
occult metastases is about 15%, and in the high-risk 
situation (with lymphovascular invasion), it is up to 
50% (statement, 2b) [e37, e39–e44, e45, e69].
15 In the low-risk situation, active surveillance is recom-
mended (A, 2b) [e70–e72].
16 In the high-risk situation, the treatment modalities in-
cluding 1 cycle of PEB versus active surveillance should 
be discussed with the patient. One cycle of PEB reduc-
es the risk of recurrence from 50 to 3%. The overall 
survival of both groups is the same. In case of individ-
ual patient’s reluctance to surveillance and adjuvant 
chemotherapy, or in case of contraindications against 
chemotherapy, primary nerve-sparing retroperitoneal 
lymph node dissection with modified field boundaries 
should be considered alternatively. It is recommended 
to perform this intervention at centres with proven ex-
perience (B, GRADE: moderate quality of the evidence) 
[e72–e74].
See Tables 5–8 for the corresponding recurrences rates.
Stage I disease with serum tumour marker increase:
17 In patients with persistently elevated serum tumour 
markers after orchiectomy (cSI), it is recommended to 
Table 7. Recurrence rates of RLA versus surveillance or 
chemotherapy in studies with non-seminomatous GCT patients in 
cSI [25, 34]













GCT, germ cell tumour; cSI, clinical stage I.
Table 8. Recurrence rates in studies with non-seminomatous GCT 
patients in cSI managed with surveillance before 1992 and after 
1993 [20, 21, 35]

















[20] 1,139 (total) 19.0
GCT, germ cell tumour; cSI, clinical stage I; hr, high risk; lr, low 
risk.
German Clinical Practice Guideline on 
Germ Cell Tumours of the Testis
179Urol Int 2021;105:169–180
DOI: 10.1159/000510407
rule out non-GCT-related causes for serum tumour 
marker elevation (expert consensus).
18 Patients with persistent tumour marker elevations af-
ter orchiectomy and negative imaging, in whom other 
causes for serum tumour marker elevation have been 
ruled out, should be closely monitored prior to treat-
ment decision-making until either an unequivocal 
continuous marker increase of AFP or β-hCG be-
comes evident or a detectable lesion upon imaging be-
comes evident (expert consensus).
Key Messages of Part I
• GCTs have an incidence of 10:100,000 men/year but represent 
25% of cancer cases diagnosed in the age group of 20–40 years.
• The patient’s prognosis essentially depends on tumour histol-
ogy, clinical stage, age, and quality of care.
• Stage I GCTs have excellent 5-year survival rates with 97.9% for 
seminoma and 94.9% for non-seminomatous GCT.
• Five-year survival rates for metastatic GCTs are 86–95% in the 
good prognosis group, 72–85% for the intermediate prognosis 
group, and 48–64% for the poor prognosis group.
• We recommend the 2016 WHO classification for histopatho-
logical evaluation of GCTs.
• We recommend the classification of metastatic GCTs based on 
the prognosis criteria of the IGCCCG classification.
• The patients’ fertility is impaired by GCT therapy to variable 
extent, depending on the treatment modality and the initial 
situation. Therefore, we recommend that cryopreservation of 
spermatozoa is offered to the patient before any treatment.
• FDG PET/CT is not recommended for routine use in primary 
staging.
• In monorchid GCNIS, local radiotherapy with 18–20 Gy erad-
icates GCNIS cells in more than 95% of cases.
• CNIS develop invasive cancer. In these cases, additional radio-
therapy should be performed.
• In seminoma cSI, all treatment options (active surveillance, ad-
juvant chemotherapy with carboplatin, and adjuvant radio-
therapy) achieve the same survival rates.
• Patients with seminoma cSI are recommended to be followed 
up by active surveillance and treated stage-adapted in the case 
of recurrence.
• In patients with non-seminomatous GCT, active surveillance is 
recommended in the low-risk situation.
• In patients with high-risk non-seminomatous GCT, 1 cycle of 
PEB reduces the risk of recurrence from 50 to 3%. The overall 
survival of both treatment options, 1 cycle of PEB versus sur-
veillance, is the same.
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